BIOGEN INC

NASDAQ: BIIB (Biogen Inc.)

Kemas kini terakhir: 30 Jan, 2:32PM

177.49

1.36 (0.77%)

  • 1H 0.77%
  • 5H -6.56%
  • 1B -9.27%
  • 6B 23.84%
  • Tahun Ke Tarikh -0.19%
  • 1T 27.28%
  • 5T -31.77%
Penutupan Terdahulu 176.13
Buka 177.09
Jumlah Dagangan 544,222
Purata Dagangan (3B) 1,970,339
Modal Pasaran 26,037,452,800
Harga / Pendapatan (P/E TTM) 16.16
Harga / Pendapatan (P/E Ke hadapan) 12.14
Harga / Jualan (P/S) 2.83
Harga / Buku (P/B) 1.53
Julat 52 Minggu
110.04 (-38%) — 190.20 (7%)
Tarikh Pendapatan 6 Feb 2026
Margin Keuntungan 15.07%
Margin Operasi (TTM) 28.05%
EPS Cair (TTM) 10.12
Pertumbuhan Hasil Suku Tahunan (YOY) 6.10%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -38.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 39.00%
Nisbah Semasa (MRQ) 1.44
Aliran Tunai Operasi (OCF TTM) 2.58 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 3.43 B
Pulangan Atas Aset (ROA TTM) 5.43%
Pulangan Atas Ekuiti (ROE TTM) 9.19%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Bercampur
Drug Manufacturers - General (Global) Menaik Bercampur
Stok Biogen Inc. Menaik Menurun

AISkor Stockmoo

-0.6
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -4.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 0.5
Purata -0.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BIIB 26 B - 16.16 1.53
GRFS 8 B 1.91% 14.00 0.910
AZN 301 B 0.27% 29.75 6.21
SNY 109 B 4.92% 19.15 1.28
AMGN 198 B 2.63% 25.83 23.51
GILD 180 B 1.63% 21.41 7.98

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Mid Value
% Dimiliki oleh Orang Dalam 0.19%
% Dimiliki oleh Institusi 92.79%
Julat 52 Minggu
110.04 (-38%) — 190.20 (7%)
Julat Harga Sasaran
177.00 (-0%) — 246.00 (38%)
Tinggi 246.00 (Guggenheim, 38.60%) Beli
Median 207.50 (16.91%)
Rendah 177.00 (Piper Sandler, -0.27%) Pegang
Purata 208.21 (17.31%)
Jumlah 6 Beli, 8 Pegang
Harga Purata @ Panggilan 191.85
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Barclays 20 Feb 2026 185.00 (4.23%) Pegang 192.03
Wedbush 10 Feb 2026 187.00 (5.36%) Pegang 188.99
09 Feb 2026 187.00 (5.36%) Pegang 193.81
BMO Capital 09 Feb 2026 196.00 (10.43%) Pegang 193.81
Canaccord Genuity 09 Feb 2026 230.00 (29.59%) Beli 193.81
Citigroup 09 Feb 2026 215.00 (21.14%) Pegang 193.81
27 Jan 2026 185.00 (4.23%) Pegang 174.12
Guggenheim 09 Feb 2026 246.00 (38.60%) Beli 193.81
HC Wainwright & Co. 09 Feb 2026 228.00 (28.46%) Beli 193.81
Piper Sandler 09 Feb 2026 177.00 (-0.27%) Pegang 193.81
RBC Capital 09 Feb 2026 233.00 (31.28%) Beli 193.81
TD Cowen 09 Feb 2026 215.00 (21.14%) Beli 193.81
Truist Securities 09 Feb 2026 193.00 (8.74%) Pegang 193.81
08 Jan 2026 190.00 (7.05%) Pegang 186.00
Wells Fargo 09 Feb 2026 200.00 (12.69%) Pegang 193.81
Oppenheimer 30 Jan 2026 225.00 (26.77%) Beli 179.89
UBS 07 Jan 2026 185.00 (4.23%) Pegang 186.91
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
04 Feb 2026 Pengumuman Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
04 Feb 2026 Pengumuman Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
28 Jan 2026 Pengumuman Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
28 Jan 2026 Pengumuman Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
25 Jan 2026 Pengumuman FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
12 Jan 2026 Pengumuman Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
12 Jan 2026 Pengumuman Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
22 Dec 2025 Pengumuman The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
22 Dec 2025 Pengumuman The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda